NEW YORK, March 27, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany
Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ:
ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Novo Nordisk A/S Analyst Notes
On March 14, 2014, Novo Nordisk
A/S (Novo Nordisk) reported a DKK550
million (or $100 million)
investment in a new research and development facility in Bagsværd,
Denmark for increasing its drug
development capacity. The Company stated that the purification
plant will enhance its capacity to produce active pharmaceutical
ingredients for a growing number of diabetes drugs under
development. Novo Nordisk informed that the pilot plant will be
fully operational by late 2016 and will be run by CMC Supply
(Chemistry, Manufacturing and Control Supply) - a unit within Novo
Nordisk R&D. The full analyst notes on Novo Nordisk A/S are
available to download free of charge at:
http://www.AnalystsReview.com/03272014/NVO/report.pdf
--
HEALTHSOUTH Corp. Analyst Notes
On March 20, 2014, HEALTHSOUTH
Corporation (HealthSouth) announced that it will report its Q1 2014
financial results on April 28, 2014,
after the market close. The Company added that in conjunction with
the earnings release, it will host an investor conference call at
9:00 a.m. ET on April 29, 2014, Tuesday, to discuss the results.
Additionally, HealthSouth stated that the webcast of the conference
call, as well as its replay, will be available at the Company's
website. The full analyst notes on HEALTHSOUTH Corp. are available
to download free of charge at:
http://www.AnalystsReview.com/03272014/HLS/report.pdf
--
Albany Molecular Research Inc. Analyst Notes
On March 24, 2014, Albany
Molecular Research Inc. (AMRI) announced the signing of a
definitive agreement for acquisition of all the outstanding shares
of Cedarburg Pharmaceuticals, Inc. (Cedarburg) for $38.2 million in cash, in a transaction valued at
$41 million. Commenting on the
acquisition, William S. Marth,
AMRI's President and CEO, stated, "We are very excited to be
joining efforts with Cedarburg as they bring a unique blend of
expertise in complex API, a scalable business infrastructure and
extensive customer relationships that will augment our existing
capabilities and services. This transaction represents an important
first step in building out our API capabilities, broadens our
offerings and customer base and provides us with an ideal platform
to pursue additional value creation opportunities." The Company
informed that it expects the transaction to close in early
April 2014. AMRI stated that the
acquisition is expected to add between $13
million and $14 million to its 2014 revenue, based on the
anticipated timing of the close. The Company added that it also
anticipates the acquisition to be accretive to its 2014 adjusted
diluted EPS in the range of $0.06 to
$0.07 per share. The full analyst notes on Albany Molecular
Research Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03272014/AMRI/report.pdf
--
Abiomed Inc. Analyst Notes
On March 20, 2014, Abiomed, Inc.
(Abiomed) announced that it has completed the patient enrollment in
RECOVER RIGHT, an Investigational Device Exemption (IDE) study of
Impella® RP (Right Peripheral). The Company stated that the trial
was designed to enroll 30 patients, at 15 sites, for up to 14 days
of circulatory support. Commenting on the enrollment completion,
Michael R. Minogue, Chairman,
President and CEO of Abiomed stated, "We are extremely grateful for
the support from the study's principal investigators, Dr.
Mark Anderson, at Einstein Medical
Center Philadelphia and Dr. William
O'Neill at Henry Ford Hospital, as well as the other
investigators involved in this trial. The dedication from these
investigators has led to the completion of patient enrollment and
will enable data analysis and submission for a HDE with anticipated
approval in early 2015." Abiomed added that after the completion of
patient enrollment, the Company will submit the compiled data and
seek approval for a Continuous Access Protocol to enable the 15
approved Impella RP sites to continue enrolling a limited number of
patients that meet the criteria and protocol. The full analyst
notes on Abiomed Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03272014/ABMD/report.pdf
--
Geron Corporation Analyst Notes
On March 20, 2014, Geron Corp.
(Geron) announced that patients currently enrolled in the
investigator-sponsored clinical trial of imetelstat in
myelofibrosis (Myelofibrosis IST) who are deriving clinical benefit
may continue imetelstat treatment under a partial clinical hold
placed by the U.S. Food and Drug Administration (FDA). The Company
informed that a partial clinical hold means that no new patients
may be enrolled into the Myelofibrosis IST, and patients currently
enrolled must demonstrate that they are deriving clinical benefit
in order to continue taking imetelstat. Geron stated that the
reason cited by the FDA for the partial clinical hold was that a
safety signal of hepatotoxicity had been identified in clinical
trials of imetelstat, and that it is not known if this
hepatotoxicity is reversible. The Company added that it expects to
provide an update regarding its clinical hold during the first
quarter conference call. The full analyst notes on Geron
Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03272014/GERN/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review